Tuesday, December 3, 2024
Home Oncology & Cancer Extended PSMA therapy safe and effective for prostate cancer patients, research finds

Extended PSMA therapy safe and effective for prostate cancer patients, research finds

by Medical Xpress
0 comment


Credit: Journal of Nuclear Medicine (2024). DOI: 10.2967/jnumed.123.267321

Extended prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (177Lu-PSMA) beyond six cycles is an effective and well-tolerated treatment for metastatic castration-resistant prostate cancer patients, according to new research published in the Journal of Nuclear Medicine.

Selected patients who received extended treatment—either continuously or following a treatment break—experienced a favorable median survival of 31.3 months from the first administration.

“Patient response to PSMA-targeted radiopharmaceutical therapy is highly variable in depth and duration of response,” said Wolfgang P. Fendler, MD, vice chair of the Department of Nuclear Medicine at the University Hospital Essen, in Essen, Germany.

“It may be beneficial to extend the use of 177Lu-PSMA, however, systematic data on safety and the antitumor effect of 177Lu-PSMA radiopharmaceutical therapy beyond six cycles is scarce.”

The multicenter retrospective analysis included 111 metastatic castration-resistant prostate cancer patients who received more than six cycles of 177Lu-PSMA. Forty-three patients (38.7%) received continuous 177Lu-PSMA treatment and 68 (71.3%) received rechallenge treatment after a therapy break of at least four months.

Researchers assessed overall survival, (PSA) decline, PSMA PET response, and adverse events to determine the safety and efficacy of extended 177Lu-PSMA therapy.

Overall survival from the initiation of 177Lu-PSMA therapy was 23.2 months for the continuous treatment group and 40.2 months for the rechallenge group; the for both groups was 31.3 months. The PSA decline of more than 50% and the initial partial response rate on PSMA PET was significantly higher in the rechallenge group than in the continuous treatment group. Rates of grade three to four toxicity were comparable between both groups.

“This study represents the inaugural multicenter investigation of extended 177Lu-PSMA therapy, encompassing up to 13 cycles of treatment, continuously or following a treatment break. Dose reduction and discontinuation rates due to adverse events were low and patients achieved durable responses after treatment pause,” said Tugce Telli, MD, researcher at University Hospital Essen.

“Given the limited treatment options for metastatic castration-resistant prostate cancer, the extension or retreatment of 177Lu-PSMA beyond six cycles may be a valuable option for patients who initially have a good or excellent response to treatment.”

More information:
Robert Seifert et al, Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study, Journal of Nuclear Medicine (2024). DOI: 10.2967/jnumed.123.267321

Provided by
Society of Nuclear Medicine & Molecular Imaging

Citation:
Extended PSMA therapy safe and effective for prostate cancer patients, research finds (2024, June 4)
retrieved 4 June 2024
from https://medicalxpress.com/news/2024-06-psma-therapy-safe-effective-prostate.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

You may also like

Leave a Comment

Edtior's Picks

Latest Articles

All Rights reserved, site designed by Yellohost.co.za